Indivior Pharmaceuticals layoffs, on the record
Every job cut, severance charge and restructuring Indivior Pharmaceuticals reported in its annual reports, 2023 to 2025, quoted from the filings. Headcount went from 1,164 to 1,051.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 20-F for 2023 | 1,164 | December 31, 2023 |
| 10-K for 2024 | 1,051 | December 31, 2024 |
Job cuts, severance and restructuring
Our summaryThe filing's exceptional items table shows restructuring costs of 2 million recorded in 2023 and none in 2022, with 1 million in 2021.
Word for word“The table below sets out exceptional items and other adjustments recorded in each period For the year ended December 31, (in millions) 2023 2022 2021 Exceptional items and other adjustments within cost of sales Amortization of acquired intangible assets (1) (8) — — Total exceptional items and other adjustments within cost of sales (8) — — Exceptional items and other adjustments within SG&A Restructuring costs (2) — — 1” 20-F for 2023
Our summaryDiscontinued promotion and marketing of PERSERIS, reducing headcount and terminating related contract manufacturing agreements.
Word for word“In July 2024, the Company announced the discontinuation of promotion and marketing support for PERSERIS, resulting in a headcount reduction of approximately 130 employees and termination of related contract manufacturing agreements.” 10-K for 2024
Our summaryRecorded PERSERIS-related charges of $53 million, including inventory provisions, impairment, contract termination costs and severance.
Word for word“Charges of $ 53 million recorded in 2024 included inventory provisions and impairment of tangible assets, contract termination costs and severance.” 10-K for 2024
Our summaryRecorded severance costs within selling, general and administrative expenses.
Word for word“In 2024, selling, general and administrative costs reflect $12 million of costs related to the discontinuation of sales and marketing for PERSERIS and $12 million of severance costs.” 10-K for 2024
Our summaryAnnounced that the CEO would step down as CEO and Board Director by mutual agreement, with a separation agreement providing one-year severance.
Word for word“The Separation Agreement includes a one-year severance, continuation of benefits, and allows for potential vesting of all share-based compensation awards to the extent the original grant date market conditions met.” 10-K for 2024
Our summaryAnnounced a restructuring of its Research & Development and Medical Affairs organizations, including closing three related locations.
Word for word“Restructuring of Research & Development and Medical Affairs organizations In August 2025, we announced that we would restructure our Research & Development and Medical Affairs organizations.” 10-K for 2025
Our summaryAnnounced it would stop operating and selling its products in several markets outside the U.S.
Word for word“Rest of World Optimization In October 2025, we announced that we would cease operations and discontinue the sale of our products in several markets, including the U.K., Ireland, Sweden, Israel, Finland, and Italy.” 10-K for 2025
Our summaryRecognized exit costs in 2025 from the R&D and medical affairs restructuring, the OPVEE discontinuation and the Rest of World optimization, including severance and related employee exit charges.
Word for word“As a result of these actions, we recognized exit costs of $127 million in 2025, including (i) severance and related employee exit charges, (ii) the consolidation and exit of certain real estate properties, including write-downs of leasehold improvements, fixed assets, and acceleration of leased property restoration costs, (iii) write-downs of intangible assets and inventory, (iv) contract termination and related costs, and (v) consulting services, among others.” 10-K for 2025
Indivior Pharmaceuticals filed 2 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Indivior Pharmaceuticals’s annual reports (10-K for 2025, 10-K for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.